Abstract:AIM:To assess the efficacy and safety of standard triple therapy compared with other pre-existing and new therapies in China. METHODS:Literature searches were conducted in the following databases: PubMed, EMBASE, the Cochrane Central Register of Controlled Trials, the VIP database, the China National Knowledge Infrastructure database, and the Chinese Biomedical Database.A meta-analysis of all randomized controlled trials (RCTs) comparing standard triple therapy for the eradication of Helicobacter pylori with pre-existing and new therapies in China was performed using Comprehensive Meta-Analysis 2.0.There were 49 studies that met our criteria and the qualities of these studies were assessed using the Jadad scale.The Mantel-Haenszel method was used for pooling dichotomous data.We also conducted subgroup analyses according to age, duration of treatment and drug type.Sensitivity analyses and a cumulative metaanalysis were also performed with CMA 2.0.Publication bias was evaluated using Egger's test, Begg's test or a funnel plot. RESULTS:A total of 49 RCTs including 8332 patients were assessed.This meta-analysis showed that standard triple therapy with proton pump inhibitors (PPIs), amoxicillin (AMO) and clarithromycin (CLA) was inferior to sequential therapy [relative risk (RR) = 0.863; 95% confidence interval (CI): 0.824-0.904],but was not superior to quadruple therapy (RR = 1.073; 95%CI: 0.849-1.357)or other triple therapies (RR = 1.01; 95%CI: 0.936-1.089).The meta-analysis also suggested that standard triple therapy is slightly more effective than dual therapy (RR = 1.14; 95%CI: 0.99-1.31).However, the differences were not statistically significant.We removed the only trial with a regimen lasting 14 d by sensitivity analysis and found that 7-d standard triple therapy was superior to 7-d dual therapy (RR = 1.222; 95%CI: 1.021-1.461).Moreover, a sub-analysis based on the duration of quadruple therapy indicated that the 7-d and 10-d standard triple therapies were inferior to sequential therapy (RR = 0.790; 95%CI: 0.718-0.868;RR = 0.917; 95%CI: 0.839-1.002,respectively).Additionally, there were no significant differences in cure rate or adverse events among standard triple therapy, quadruple therapy, and other triple therapies (RR = 0.940; 95%CI: 0.825-1.072;RR = 1.081; 95%CI: 0.848-1.378,respectively).Standard triple therapy had a higher occurrence of side effects than sequential therapy (RR = 1.283; 95%CI: 1.066-1.544). CONCLUSION:The eradication rates with a standard triple therapy consisting of PPI, AMO, and CLA are suboptimal in China, and new treatment agents need to be developed.

The efficacy of moxifloxacin-based triple therapy in treatment of Helicobacter pylori infection: a systematic review and meta-analysis of randomized clinical trials.

Advantages of Moxifloxacin and Levofloxacin-based Triple Therapy for Second-Line Treatments of Persistent Helicobacter Pylori Infection: a Meta Analysis

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials.

Azithromycin-containing Versus Standard Triple Therapy for Helicobacter Pylori Eradication: a Meta-Analysis.

The effect of antibiotic resistance on Helicobacter pylori eradication efficacy: A systematic review and meta‐analysis

Comparative Effectiveness And Tolerance Of Treatments For Helicobacter Pylori: Systematic Review And Network Meta-Analysis

Antofloxacin-based Bismuth Quadruple Therapy is Safe and Effective in Helicobacter Pylori Eradication: A Prospective, Open-Label, Randomized Trial

[Levofloxacin-Based Triple Therapy for First-Line Helicobacter Pylori Eradication Treatment: a Multi-Central, Randomized, Controlled Clinical Study].

Novel Information Regarding the Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Meta-Analysis: Lactobacillus Containing Quadruple Therapy Versus Standard Triple First-Line Therapy For Helicobacter Pylori Eradication

Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection

Levofloxacin-based triple regimens in rescue the treatment for H.pylori eradication:a meta-analysis

Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of <i>Helicobacter pylori</i> Infection A Meta-Analysis of Randomized Controlled Trials

Efficacy and safety of minocycline quadruple therapy for Helicobacter pylori eradication: A meta-analysis of RCTs

Meta-analysis: is Combination of Tetracycline and Amoxicillin Suitable for Helicobacter Pylori Infection?

Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.

High-Dose Dual Therapy Versus Bismuth-Containing Quadruple Therapy for the Treatment of Helicobacter pylori Infection: A Systematic Review with Meta-Analysis

Efficacy of Levofloxacin, Metronidazole and Bismuth-containing quadruple therapy for eradication of Helicobacter pylori

The research of 3-day Moxifloxacin-based short-term triple thereapies for the eradication of Helicobacter pylori infection

Standard Triple Therapy for Helicobacter Pylori Infection in China: A Meta-Analysis